GLP-1 drugs and lifestyle: what the evidence actually says

What did @dr.ssamariaritacaputo actually say?

The video's caption carries the core message: tirzepatide and semaglutide are "not shortcuts," and without consistency, nutrition, and movement, the only outcome is returning to your starting point. The phrase "il farmaco è un supporto, non la soluzione" translates to "the medication is support, not the solution." That is the actual claim being made here.

It is worth noting upfront that the audio transcript provided for this video does not match the caption content at all. The spoken words appear to be unrelated to GLP-1 medications entirely, which raises a real question about whether the educational content was delivered in text overlays, voiceover, or a different language track. The fact-check below is therefore based on the written caption claims, which represent what viewers were likely reading and internalizing.

Does the science back this up?

Yes, largely. The claim that GLP-1 receptor agonists require lifestyle support to prevent weight regain after stopping is well-supported. The evidence on rebound weight gain post-discontinuation is consistent and hard to ignore.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed participants who stopped semaglutide after 68 weeks. Within one year of discontinuation, participants regained roughly two-thirds of the weight they had lost. Cardiometabolic improvements also reversed. This is not a fringe finding. A separate analysis published by Rubino et al. (2021, JAMA) confirmed that weight regain after GLP-1 cessation is real and significant. The underlying biology here matters: these medications suppress appetite via GLP-1 and GIP receptor pathways, but they do not permanently reset the body's adiposity setpoint. When the drug stops, hunger signals and metabolic adaptations that favor fat storage return. So the creator's warning about the "yo-yo effect" has a legitimate physiological basis.

What did they get wrong (or right)?

They got the headline right. GLP-1 agonists are not standalone solutions, and framing them as a "support" rather than a cure is accurate and responsible. That framing also happens to align with how regulatory agencies and clinical guidelines position these drugs.

Where this gets more complicated is the implicit suggestion that lifestyle changes alone can fully prevent weight regain after stopping the medication. The data suggest this is harder than it sounds. Even participants in structured behavioral programs struggle to maintain losses after GLP-1 discontinuation. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide regained substantial weight despite continued lifestyle interventions. So while the creator is right to emphasize lifestyle, it would be misleading to imply that effort alone fully compensates for coming off the drug. The biology is working against you in ways that willpower does not simply override.

There is also nothing in this content that crosses into dangerous territory. No dosing claims, no disease cure promises, no compounded vs. brand-name equivalency assertions. Credit where it is due.

What should you actually know?

GLP-1 receptor agonists are among the most effective pharmacological tools currently available for weight management. Semaglutide (Wegovy) produced average losses of around 15 percent of body weight in STEP 1 (Wilding et al., 2021, NEJM). Tirzepatide (Zepbound) showed up to 22.5 percent average loss at the highest dose in SURMOUNT-1 (Jastreboff et al., 2022, NEJM). These are not trivial numbers.

But the creator is pointing at a real clinical tension: these drugs work extremely well while you are on them, and stopping them without a clear plan tends to undo much of that progress. The current thinking among obesity medicine specialists is that for many patients, long-term or indefinite use may be necessary, similar to how we treat other chronic conditions like hypertension. The "medication as support, not solution" framing, while motivationally useful, can inadvertently suggest that the goal is always to eventually come off the drug. For some patients, that framing may not be clinically accurate.

• Weight regain after stopping semaglutide averages around 11.6 percentage points within one year (Wilding et al., 2022, NEJM).
• Lifestyle intervention alone does not fully prevent this rebound in most patients.
• These medications are approved for chronic weight management, meaning long-term use is within the intended clinical scope.
• Anyone considering starting or stopping these medications should do so with a licensed prescriber, not based on social media guidance.